Schizophrenia

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. DOI: 10.1016/j.schres.2005.07.014. PubMed PMID: 16137860.

A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Barnes TRE, Paton C, Cavanagh M-R, Hancock E, Taylor DM. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull. 2007;33(6):1397-403. DOI: 10.1093/schbul/sbm038. PubMed PMID: 17483101; PubMed Central PMCID: PMC2779874.

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Shahid M, Walker GB, Zorn SH, Wong EHF. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73. DOI: 10.1177/0269881107082944. PubMed PMID: 18308814.

Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia.

Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2-3):109-13. DOI: 10.1016/j.psychres.2009.05.004. PubMed PMID: 20185182.

Increased cardiovascular risk in patients with severe mental illness.

Gladigau EL, Fazio TN, Hannam JP, Dawson LM, Jones SG. Increased cardiovascular risk in patients with severe mental illness. Intern Med J. 2014;44(1):65-9. DOI: 10.1111/imj.12319. PubMed PMID: 24383746.

Fluphenazine outpatient clinics: a pharmacist's role.

Bond CA, Salinger RJ. Fluphenazine outpatient clinics: a pharmacist's role. J Clin Psychiatry. 1979;40(12):501-3. PubMed PMID: 500572.

Schizophrenia and increased risks of cardiovascular disease.

Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Hear J. 2005;150(6):1115-21. DOI: 10.1016/j.ahj.2005.02.007. PubMed PMID: 16338246.

A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007;64(10):1123-31. DOI: 10.1001/archpsyc.64.10.1123. PubMed PMID: 17909124.

Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.

Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. Bmc Psychiatrybmc Psychiatry. 2013;13:246. DOI: 10.1186/1471-244X-13-246. PubMed PMID: 24094241; PubMed Central PMCID: PMC3853885.

Assessment and treatment selection for "revolving door" inpatients with schizophrenia.

Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q. 1997;68(4):377-92. PubMed PMID: 9355136.